India-based global pharmaceutical company Dr. Reddy's Laboratories has launched Zoledronic Acid injection (4 mg/5 mL), following the approval of its abbreviated new drug application (ANDA) from the Food and Drug Administration, in the US.
Zoledronic Acid Injection (4 mg/5 mL) is generic bioequivalent to Novartis Oncology's Zometa (zoledronic acid) injection in the same strength.
Zometa is intended for use to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, and treat osteoporosis.
Dr. Reddy's said Zoledronic Acid injection is available in a single use vial of concentrate.
Dr. Reddy offers a portfolio of products and services including active ingredients, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
